Search
Returning search results with filters:
Remove filter for
Audience: Health professionals
Remove filter for
Category: Drugs
Remove filter for
Issue: Product safety
Remove filter for
Last updated: 2022
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Recall class
Displaying 1 - 12 of 12 items.
Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy
AlertHealth professional risk communication | 2022-10-31
IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure
AlertHealth professional risk communication | 2022-08-29
PMS-Hydromorphone: Affected lot may contain tablets that could potentially lead to overdose
RecallHealth product recall | 2022-08-22
Recall of one lot of pms-Hydromorphone due to packaging error that could potentially lead to overdose
AlertPublic advisory | 2022-08-20
Sodium Acetate Injection, USP - Potential for the Presence of Particulate Matter
AlertHealth professional risk communication | 2022-03-15
0.9% Sodium Chloride Injection, USP and Lactated Ringer’s Injection, USP - Potential Leak During Pressure Infusion
AlertHealth professional risk communication | 2022-03-09
Distribution of NUVAXOVID with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2022-02-23
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
AlertHealth professional risk communication | 2022-02-03
APO-AMITRIPTYLINE 10mg: NDMA impurity
RecallHealth product recall | 2022-01-26
ELAVIL 10mg: NDMA impurity
RecallHealth product recall | 2022-01-26
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
AlertHealth professional risk communication | 2022-01-12